Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.
Gregory Vidal, MD, PhD
Advertisement
Articles by Gregory Vidal, MD, PhD
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology
3
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
4
Epcoritamab Plus Lenalidomide Improves PFS vs R-GemOx in R/R DLBCL
5